Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis
ABSTRACT Background and Aims Concomitant administration of trastuzumab (Tra) and radiotherapy (RT) has been known as an effective strategy for treating HER2‐positive breast cancer (HER2+ BC) patients. Studies have investigated the incidence of cardiotoxicity due to this concomitant treatment, but th...
Saved in:
| Main Authors: | Ali Jabbari, Elham Mousavi, Majid Nikoubin‐Boroujeni, Shabnam Tabasi, Nazila Arjmandi, Noura Ghelishli, Zahra Arab‐Bafrani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.70966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study
by: K. Debbi, et al.
Published: (2025-04-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01) -
Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01) -
Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer
by: Mania Makhoul, et al.
Published: (2025-07-01) -
Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)